Can Fite Biopharma Stock Net Income
| CANF Stock | USD 4.47 0.13 3.00% |
As of the 27th of January, Can Fite shows the Standard Deviation of 7.1, risk adjusted performance of (0.1), and Mean Deviation of 4.87. Can Fite Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Can Fite Biopharma variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Can Fite Biopharma is priced correctly, providing market reflects its regular price of 4.47 per share. Given that Can Fite has information ratio of (0.15), we suggest you to validate Can Fite Biopharma's prevailing market performance to make sure the company can sustain itself at a future point.
Can Fite Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.0998 | Revenue | Quarterly Revenue Growth (0.36) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.1 M | -7.4 M | |
| Net Loss | -9.1 M | -9.5 M | |
| Net Loss | -11.7 M | -12.3 M | |
| Net Income Per E B T | 0.90 | 0.78 |
Can | Net Income | Build AI portfolio with Can Stock |
Latest Can Fite's Net Income Growth Pattern
Below is the plot of the Net Income of Can Fite Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Can Fite Biopharma financial statement analysis. It represents the amount of money remaining after all of Can Fite Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Can Fite's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.88 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Can Net Income Regression Statistics
| Arithmetic Mean | (7,857,583) | |
| Coefficient Of Variation | (38.00) | |
| Mean Deviation | 2,232,344 | |
| Median | (7,092,000) | |
| Standard Deviation | 2,985,823 | |
| Sample Variance | 8.9T | |
| Range | 10.8M | |
| R-Value | (0.44) | |
| Mean Square Error | 7.7T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | (259,517) | |
| Total Sum of Squares | 142.6T |
Can Net Income History
Other Fundumenentals of Can Fite Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Can Fite Net Income component correlations
Can Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Can Fite is extremely important. It helps to project a fair market value of Can Stock properly, considering its historical fundamentals such as Net Income. Since Can Fite's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Can Fite's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Can Fite's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Can Fite 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Can Fite's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Can Fite.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Can Fite on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Can Fite Biopharma or generate 0.0% return on investment in Can Fite over 90 days. Can Fite is related to or competes with Kazia Therapeutics, CNS Pharmaceuticals, Clearmind Medicine, Soligenix, GRI Bio, Oragenics, and Silo Pharma. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for th... More
Can Fite Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Can Fite's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Can Fite Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 |
Can Fite Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Can Fite's standard deviation. In reality, there are many statistical measures that can use Can Fite historical prices to predict the future Can Fite's volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | 0.6041 |
Can Fite January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 0.6141 | |||
| Mean Deviation | 4.87 | |||
| Coefficient Of Variation | (697.57) | |||
| Standard Deviation | 7.1 | |||
| Variance | 50.36 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.71) | |||
| Treynor Ratio | 0.6041 | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 | |||
| Skewness | (0.04) | |||
| Kurtosis | 2.66 |
Can Fite Biopharma Backtested Returns
Can Fite Biopharma secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of risk over the last 3 months. Can Fite Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Can Fite's Risk Adjusted Performance of (0.1), mean deviation of 4.87, and Standard Deviation of 7.1 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.7, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Can Fite are expected to decrease by larger amounts. On the other hand, during market turmoil, Can Fite is expected to outperform it. At this point, Can Fite Biopharma has a negative expected return of -0.83%. Please make sure to confirm Can Fite's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Can Fite Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.39 |
Below average predictability
Can Fite Biopharma has below average predictability. Overlapping area represents the amount of predictability between Can Fite time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Can Fite Biopharma price movement. The serial correlation of 0.39 indicates that just about 39.0% of current Can Fite price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.29 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Can Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Can Fite Biopharma reported net income of (7.88 Million). This is 102.31% lower than that of the Biotechnology sector and 111.25% lower than that of the Health Care industry. The net income for all United States stocks is 101.38% higher than that of the company.
Can Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in net income category among its peers.
Can Fite Current Valuation Drivers
We derive many important indicators used in calculating different scores of Can Fite from analyzing Can Fite's financial statements. These drivers represent accounts that assess Can Fite's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Can Fite's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 21.7M | 17.2M | 9.5M | 11.3M | 13.1M | 12.4M | |
| Enterprise Value | 17.4M | 14.2M | 5.3M | 6.6M | 7.6M | 7.2M |
Can Fite ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Can Fite's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Can Fite's managers, analysts, and investors.Environmental | Governance | Social |
Can Fundamentals
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (24.25) % | ||||
| Current Valuation | (2.62 M) | ||||
| Shares Outstanding | 17.07 M | ||||
| Shares Owned By Institutions | 5.53 % | ||||
| Number Of Shares Shorted | 51.4 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 7.09 X | ||||
| Revenue | 674 K | ||||
| Gross Profit | 560 K | ||||
| EBITDA | (8.12 M) | ||||
| Net Income | (7.88 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 104 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Short Ratio | 0.19 X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.042 | ||||
| Market Capitalization | 15.24 M | ||||
| Total Asset | 9.12 M | ||||
| Retained Earnings | (166.36 M) | ||||
| Working Capital | 6.93 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
| Net Asset | 9.12 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Can Fite Piotroski F Score and Can Fite Altman Z Score analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.